Skip to content

Intravenous Dexamethasone for Preventing Post Operative Nausea and Vomiting in Total Abdominal Hysterectomy: A Randomized Control Trial

Intravenous Dexamethasone for Preventing Post Operative Nausea and Vomiting in Total Abdominal Hysterectomy: A Randomized Control Trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230410007
Enrollment
86
Registered
2023-04-10
Start date
2022-08-11
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1.Known hypersensitivity to dexamethasone. 2 .There are conditions that might influence gastrointestinal mobility including abdominal bowel surgery, previous abdominal irradiation. 3.Other gastrointestinal disorders (pancreatitis, peritonitis, hypothyroid, chronic use of opiate, musculoskeletal disorders and chronic use of drugs which impact intestinal peristalsis). 4.Patient underlying of diabetes who got poor control of glycemic control having HbA1Cmore than 8, moderate degrees of diabetic

Interventions

1.Patients are eligible if they undergo a benign total abdominal hysterectomy with or without adnexal surgery. The patients are informed by researcher assistant about the study and ask for their conse
Experimental Drug
Dexamethasone

Sponsors

Khon Kaen Hospital Institute Review Board in Human Research
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Women age >18 years old. 2.Patient who underwent benign total abdominal hysterectomy with or without adnexal surgery. 3.Patient who understands Thai language.

Exclusion criteria

Exclusion criteria: 1.Known hypersensitivity to dexamethasone. 2 .There are conditions that might influence gastrointestinal mobility including abdominal bowel surgery, previous abdominal irradiation. 3.Other gastrointestinal disorders (pancreatitis, peritonitis, hypothyroid, chronic use of opiate, musculoskeletal disorders and chronic use of drugs which impact intestinal peristalsis). 4.Patient underlying of diabetes who got poor control of glycemic control having HbA1Cmore than 8, moderate degrees of diabetic of retinopathy, impaired of visual acuity, history of wound resulting from diabetes at foot, history of foot amputation, claudication of lower limbs. 5.Patient who got immunocompromised host (Tubercolosis, Viral Infection) 6.Intraoperation blood loss of more than 1,000 ml or blood loss that requires blood transfusion.

Design outcomes

Primary

MeasureTime frame
Incidence of PONV at 24 hours after surgery (n%) 24 hours after surgery Patient reported outcome using a questionnaire interview

Secondary

MeasureTime frame
Additional antiemetics requirements(n%) 24 hours after surgery Patient reported outcome using a questionnaire interview,Additional analgesic requirements(n%) 24 hours after surgery Patient reported outcome using a questionnaire interview,Side effects of dexamethasone(n%) 24 hours after surgery Patient reported outcome using a questionnaire interview,Analgesic effect measure by VAS mean(SD) 24 hours after surgery Patient reported outcome using Visual Analogue Scale,The duration of hospital stay (hours) mean (SD) 24 hours after surgery Patient reported outcome using a questionnaire interview

Countries

Thailand

Contacts

Public ContactKanyawee Suhongsa

Khon Kaen Hospital

kanyawee.suh@gmail.com0809432310

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026